This study investigates the response of pancreatic cancer to a specific treatment plan before surgery, known as neoadjuvant therapy. Pancreatic cancer is a disease where cancerous cells form in the tissues of the pancreas, an organ located behind the stomach that helps in digestion and blood sugar regulation. The study focuses on patients who have pancreatic cancer that can be surgically removed, known as resectable pancreatic cancer.

Participants will receive a treatment called FOLFIRINOX before surgery. FOLFIRINOX is a combination of chemotherapy drugs used to shrink tumors. The study includes collecting tissue samples to evaluate the effectiveness of the treatment in achieving a pathologic complete response, which means no cancer cells are found in tissue samples after treatment.

• Who can participate: Participants must have pancreatic cancer that can be surgically removed. Age criteria should be included if available.
• Study details: Participants will receive FOLFIRINOX, a combination of chemotherapy drugs, before surgery. Tissue samples will be collected to assess the treatment response.